None listed
Conditions
Brief summary
This trial tested whether a shorter duration of 7 days could be as effective as 14 days of primaquine in vivax malaria patients. Treatment response and relapse rates were compared to evaluate the ability of reduced treatment duration to achieve similar effects. We posited that 7-day regimens are not inferior to standard 14-day regimens.
Interventions
Participants in the intervention group will receive a 7-day regimen of primaquine at a dose of 1 mg/kg/day, administered orally. Drug adherence will be ensured through direct observation of therapy (DOT) during hospitalization and drug tablet count post-discharge. Allocation to treatment was non-randomized and determined by alternate allocation based on enrolment order.
Sponsors
Hayatabad Medical Complex, Peshawar
Study design
Allocation
Non-randomised trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 76 Years
Healthy volunteers
No
Inclusion criteria
Patients of age 18 years and above, including both genders diagnosed with P. vivax malaria confirmed by peripheral smear examination/malaria fluorescent test, were included in the study.
Exclusion criteria
The study excluded pregnant or lactating mothers, patients with G6PD deficiency, bleeding diathesis or haemolytic anaemias, severe complicated malaria, hypersensitivity to drugs, those using drugs that could interact with primaquine, and those who had recently received a blood transfusion (in the previous 90 days).
Outcome results
None listed